The role of flumazenil infusion in the treatment of benzodiazepine withdrawal

Phase 2

• Conditions: Benzodiazepine withdrawal; Mental Health - Addiction

• Registration Number: ACTRN12616001560482
• Lead Sponsor: Go Medical Industries Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-11
• Study Completion: 2019-04-18
• Last Update Posted: 14 March 2022

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Patients with daily benzodiazepine use for at least 3 months at a diazepam equivalent dose of 10 mg per day or higher, who want to cease benzodiazepine use.

Exclusion Criteria

Patients will be excluded if they suffer epilepsy or have a history of seizures or fitting, are pregnant or are breastfeeding, are co-dependent on alcohol, are under 18 years of age or are unable or unwilling to provide informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of symptom-triggered taper from benzodiazepines, as assessed by daily diazepam dose required. [Reduction in daily diazepam dose from day 1 to day 8 of active treatment compared to reduction from day 1 to day 8 of placebo treatment. ]